Aeolus Pharmaceuticals Announces Date and Time for Barda Contract and Corporate Update Conference Call

MISSION VIEJO, CA--(Marketwire - Apr 5, 2012) - Aeolus Pharmaceuticals (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel compounds in oncology and biodefense, today announced the date and time for its BARDA and Corporate Update conference call.

Conference Call
Tuesday, April 10, 2012 @ 11am Pacific/2pm Eastern
Domestic: 877-837-3910, Passcode #70022069
International: 973-796-5077, Passcode #70022069

Webcast and replays: www.aeoluspharma.com

Conference Call audio replays will be available through May 10, 2012
Domestic: 855-859-2056; Passcode #70022069
International: 404-537-3406; Passcode #70022069

On the conference call, management will provide an update on the Company's business and operations, including expectations for the future. Management will include a discussion of the work completed to date on its contract with the Biomedical Advanced Research and Development Authority (BARDA) and the status of the contract options.

About Aeolus Pharmaceuticals

Aeolus Pharmaceuticals is developing a new class of catalytic antioxidant compounds that protects healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed for oncology indications, where it is used in combination with radiation therapy. It is also being developed, with funding by the US Government, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical studies made by US Government agencies in AEOL 10150 to efficiently develop the compound for use in oncology. For more information, please visit Aeolus' corporate website at www.aeoluspharma.com.

The statements in this press release that are not purely statements of historical fact are forward-looking statements. Such statements include, but are not limited to, those relating to Aeolus' product candidates, as well as its proprietary technologies and research programs and any potential future submissions or applications to the FDA. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Important factors that could cause results to differ include risks associated with uncertainties of progress and timing of clinical trials, scientific research and product development activities, difficulties or delays in development, testing, obtaining regulatory approval, the need to obtain funding for pre-clinical and clinical trials and operations, the scope and validity of intellectual property protection for Aeolus' product candidates, proprietary technologies and their uses, receipt of funding under the contract with BARDA, and competition from other biopharmaceutical companies. Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' Annual Report on Form 10-K for the year ended September 30, 2011. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.